1 active not recruiting, 1 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Hyperthyroxinemia: new trials by email Literature Review of Hyperthyroxinemia trials Research Report on Hyperthyroxinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Resmetirom - Non-Alcoholic Fatty Liver Disease | Phase 3 | Active not recruiting | Madrigal Pharmaceuticals, Inc. | 810 | 2021-07-09 | 2026-05-27 |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients Placebo, Resmetirom - Non-Alcoholic Fatty Liver Disease | Phase 3 | Completed | Madrigal Pharmaceuticals, Inc. | 1343 | 2019-12-16 | 2023-09-05 |
Dyslipidemias (2) · Fibrosis (2) · Hyperlipidemias (2) · Non-alcoholic Fatty Liver Disease (2) · Thyroid Hormone Resistance Syndrome (2)
Digestive System Diseases (2) · Endocrine System Diseases (2) · Fatty Liver (2) · Lipid Metabolism Disorders (2) · Liver Diseases (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Thyroid Diseases (2)
resmetirom (2)
Madrigal Pharmaceuticals, Inc. (2)
Puerto Rico (2) · United States (2)
Rebecca Taub, MD (1) · Tom Hare, MD (1)